Celgene Corporation  

(Public, NASDAQ:CELG)   Watch this stock  
Find more results for celg
-1.39 (-1.20%)
Real-time:   12:00PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 113.82 - 115.87
52 week 74.51 - 129.06
Open 115.56
Vol / Avg. 1.16M/5.03M
Mkt cap 91.70B
P/E 39.18
Div/yield     -
EPS 2.93
Shares 795.00M
Beta 1.09
Inst. own 83%
Jul 22, 2015
Q2 2015 Celgene Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 17, 2015
Celgene Corp Annual Shareholders Meeting - 1:00PM EDT - Add to calendar
Jun 4, 2015
Celgene Corp at Citi "Slice of the US" Conference Add to calendar
May 28, 2015
Celgene Corp at Sanford C Bernstein Strategic Decisions Conference - 3:00PM EDT - Add to calendar
May 12, 2015
Celgene Corp at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Celgene Corp at Deutsche Bank Health Care Conference
Apr 30, 2015
Q1 2015 Celgene Corp Earnings Release
Apr 30, 2015
Q1 2015 Celgene Corp Earnings Call
Mar 11, 2015
Celgene Corp at Barclays Healthcare Conference
Mar 4, 2015
Celgene Corp at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 34.55% 26.07%
Operating margin 41.18% 32.79%
EBITD margin - 38.35%
Return on average assets 16.56% 13.02%
Return on average equity 43.39% 33.02%
Employees 6,012 -
CDP Score - 85 B


86 Morris Ave
SUMMIT, NJ 07901-3915
United States - Map
+1-908-6739000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company’s commercial stage products include REVLIMID, VIDAZA, ABRAXANE, POMALYST/IMNOVID, THALOMID, ISTODAX and azacitidine for injection. The Company’s preclinical and clinical-stage pipeline includes Oral anti-inflammatory agents, OTEZLA (apremilast); Next generation thalidomide analogues, CC-122 and CC-220; Cellular therapies, PDA-001 and PDA-002; CC-486; Sotatercept and ACE-536; mTOR pathway inhibitors, CC-223 and CC-115; Epigenetic modifiers, EPZ-5676 and CC-292. Its subsidiaries are Celgene Avilomics Research and Celgene Cellular Therapeutics. The Company collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept and ACE-536 to treat anemia in patients with rare blood disorders.

Officers and directors

Robert J. Hugin Chairman of the Board, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark J. Alles President, Chief Operating Officer
Age: 56
Bio & Compensation  - Reuters
Thomas O. Daniel M.D. President, Research and Early Development
Age: 61
Bio & Compensation  - Reuters
Peter N. Kellogg Chief Financial Officer, Executive Vice President
Age: 59
Bio & Compensation  - Reuters
Jacqualyn A. Fouse Ph.D. President - Hematology & Oncology
Age: 54
Bio & Compensation  - Reuters
Perry A. Karsen Chief Executive Officer of Celgene Cellular Therapeutics
Age: 60
Bio & Compensation  - Reuters
Scott A. Smith President - Inflammation & Immunology
Age: 53
Bio & Compensation  - Reuters
Lawrence V. Stein Executive Vice President, General Counsel, Corporate Secretary
Age: 65
Bio & Compensation  - Reuters
Michael D. Casey Lead Independent Director
Age: 69
Bio & Compensation  - Reuters
Michael W. Bonney Director
Age: 56
Bio & Compensation  - Reuters